Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
METIS Innovative is a physician-founded investment firm established in 2017, dedicated to enhancing the lives of individuals suffering from neurologic illnesses through advancements in neurotechnology. The firm was co-founded by two prominent neurosurgeons, Brian A. Sidman and Dimitri Sigounas, MD, alongside Christopher Kellner, a veteran in capital accrual. This unique combination of medical expertise and financial acumen positions METIS to identify and invest in early-stage medical devices and technologies within the neurosciences sector.
As of now, METIS manages a portfolio of eight companies, focusing on early-stage investments that span pre-seed to Series A funding rounds. The firm operates with a clear mission to improve patient outcomes through innovative solutions in neurotechnology. Their approach integrates clinical insights from practicing neurosurgeons with rigorous financial analysis, allowing them to pinpoint high-potential opportunities in the market.
METIS Innovative invests in early-stage companies that are developing medical devices and technologies aimed at treating neurologic conditions. Their investment strategy is characterized by a dual focus on clinical insights and financial analysis, which enables them to identify promising opportunities in the neurotechnology space. The firm targets investments across various stages, including pre-seed, seed, seed-plus, and Series A, ensuring they engage with startups at critical points in their development.
The sectors of interest for METIS include biotech and healthcare, with a specific emphasis on innovations that address neurologic illnesses. The firm seeks to partner with founders who demonstrate a strong understanding of their market and possess a clear vision for their technology's impact. METIS values collaboration and aims to provide not just capital, but also strategic insights that can enhance the growth trajectory of their portfolio companies.
METIS Innovative's portfolio includes eight notable companies, each contributing to advancements in neurotechnology:
Brian A. Sidman: Co-Founder of METIS Innovative, Brian is a prominent neurosurgeon with extensive experience in the medical field and investment strategies.
Dimitri Sigounas, MD: Co-Founder and practicing neurosurgeon, Dimitri brings clinical insights and expertise in neurosurgery to the firm.
Christopher Kellner: Co-Founder with a background in capital accrual, Christopher enhances METIS's investment strategies with his financial acumen.
To pitch METIS Innovative, founders should use the contact form on their website. A comprehensive pitch deck is essential, including details about the technology, market analysis, and team qualifications. While specific response times are not mentioned, prompt and clear communication is encouraged.
What investment criteria does METIS Innovative use?
METIS Innovative focuses on early-stage companies developing medical devices and technologies for neurologic conditions. They look for startups that combine clinical insights with innovative solutions in neurotechnology.
How can I pitch my startup to METIS Innovative?
Founders can reach out through the contact form on their website. A well-prepared pitch deck that outlines the technology, market potential, and team background is essential.
What makes METIS Innovative different from other venture capital firms?
The unique combination of clinical expertise from practicing neurosurgeons and financial analysis sets METIS apart. This dual perspective allows them to identify high-potential opportunities in the neurotechnology sector effectively.
What is the geographic scope of METIS Innovative's investments?
While specific geographic preferences are not detailed, METIS focuses on companies that are innovating in the neurotechnology space, which may include both domestic and international startups.
What is the typical check size for investments?
METIS Innovative invests across various stages, including pre-seed, seed, seed-plus, and Series A, but specific check sizes are not disclosed.
What kind of post-investment support does METIS provide?
METIS Innovative offers strategic insights and resources to their portfolio companies, leveraging their clinical and financial expertise to enhance growth and innovation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.